About the JAK Inhibitors Drug Development Summit
With numerous clinical candidates demonstrating genuine viability in targeting the JAK/STAT pathway, join the JAK Inhibitors Drug Development Summit – the only platform dedicated to the clinical translation and optimization of JAK inhibitors.
Participate in cross-disciplinary discussions that are transforming JAK Inhibitor strategies into the best and first-in-class approaches for patients in need.
Never attended a digital summit before? No problem; you can find out more about it here.
What Did You Miss?
Take advantage of the versatility of JAK inhibitors to expand their clinical utility of across multiple diseases with Eli Lilly & National Institute of Arthritis & Musculoskeletal & Skin Diseases
Improve JAK inhibitor utility through rational trial design & patient stratification to optimize clinical outcomes with Mount Sinai School of Medicine, Sierra Oncology & University of Texas
Optimize JAK inhibitor outcomes in the golden age of dermatology drug development to accelerate the first-in-class JAK inhibitor to dermatology patients with Dermavant & Yale School of Medicine
Explore emerging modalities of JAK inhibitors for optimal route of delivery to balance exposure/safety with clinical response with Incyte, Nuogen Pharma & Portola Pharmacetucals
Discover the clinical proof of concept being built and accelerate preclinical candidates to the clinic through optimized selectivity with Celon Pharma & Galapagos
Who Attended In 2020?
